دورية أكاديمية

817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047

التفاصيل البيبلوغرافية
العنوان: 817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047
المؤلفون: Hodi, F.S., Tawbi, H.A., Lipson, E.J., Schadendorf, D., Ascierto, P.A., Matamala, L.A., Salman, P., Gutierrez, E.C., Rutkowski, P., Gogas, H.J., Lao, C.D., Menezes, J., Dalle, S., Arance Fernandez, A.M., Grob, J.J., Keidel, S., Rodriguez, S., Wang, P., Dolfi, S., Long, G.V.
المصدر: In Annals of Oncology September 2022 33 Supplement 7:S920-S921
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2022.07.943